Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that results in weakened breathing and reduced lung function. In the U.S., it is estimated that 50,000 individuals are diagnosed with IPF each year, and 140,000 are estimated to live with the disease in America.
Despite the fact that IPF is the most common form of idiopathic interstitial lung disease, it is a condition with no known cause or cure. Individuals who live with IPF often experience the disease with varying degrees of severity, and it is this variability that makes IPF particularly difficult to treat.
There remains a clear need for ongoing IPF research, and in our latest whitepaper, we offer data to advance this process. Patients in the Antidote database have provided us with insightful data regarding their demographics, treatment history, and more as part of their initiative to participate in research. This data can help researchers design impactful studies. To see what we discovered and how it can influence clinical trial enrollment, get your copy of the whitepaper at the link below.
